Table of Content

Strategic Imperatives
Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Pharmaceutical Continuous Manufacturing (CM) Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Growth Opportunity Analysis
Scope of Analysis
Segmentation
Market Trend Analysis
Market Trend Analysis (continued)
Batch Manufacturing versus CM
Batch Manufacturing versus CM (continued)
Benefits of Adopting CM
Vendor Ecosystem
Growth Drivers
Growth Restraints
CM Market Scenario
CM—Adoption Timeline (FDA)
CM—Adoption Timeline (FDA) (continued)
Current Market Scenario of CM Growth
CM—Technology Overview
Investment Trends—Partnerships and Expansions
Investment Trends—Partnerships and Expansions
Facility Expansions/Acquisitions
Facility Expansions/Acquisitions (continued)
Facility Expansions/Acquisitions (continued)
Facility Expansions/Acquisitions (continued)
Partnerships/Collaborations
Partnerships/Collaborations (continued)
Partnerships/Collaborations (continued)
Partnerships/Collaborations (continued)
Growth Opportunity Analysis—Global Pharmaceutical CM Market
Growth Metrics
Forecast Assumptions
Forecast Assumptions (continued)
Global Pharmaceutical Market
Revenue Forecast
Revenue Forecast Analysis
Revenue Forecast Analysis (continued)
Regional Perspective
Growth Opportunity Analysis—In-house versus Outsourced
Revenue Forecast—In-house versus Outsourced
Percent Revenue Forecast—In-house versus Outsourced
Revenue Forecast Analysis—In-house versus Outsourced
Revenue Forecast Analysis—In-house versus Outsourced (continued)
Growth Opportunity Analysis—Small Molecules versus Large Molecules
Revenue Forecast—Small Molecules versus Large Molecules
Percent Revenue Forecast—Small Molecules versus Large Molecules
Revenue Forecast Analysis—Small Molecules versus Large Molecules
Growth Opportunity Analysis—Drug Substance versus Drug Product
Revenue Forecast—DS versus DP (Large Molecules)
Revenue Forecast—API versus FDF (Small Molecules)
Revenue Forecast Analysis by Segments
Growth Opportunity Analysis—Competitor Assessment
Competitive Environment
Key Competitors by Region—End Users
Competitor Profiles—CDMOs Providing CM Services
Cambrex Corporation—Overview
Cambrex Corporation—Overview (continued)
SK Biotek—Overview
SK Biotek—Overview (continued)
Corden Pharma—Overview
Corden Pharma—Overview (continued)
Patheon (Thermo Fisher Scientific)—Overview
Patheon (Thermo Fisher Scientific)—Overview (continued)
Wuxi Biologics—Overview
Wuxi Biologics—Overview (continued)
Fujifilm Diosynth Biotechnologies—Overview
Fujifilm Diosynth Biotechnologies—Overview (continued)
CM—Equipment Manufacturers
CM—Equipment Manufacturers
CM—Equipment Manufacturers (continued)
Growth Opportunity Universe
Growth Opportunity 1—Capability Expansion for CM in APAC
Growth Opportunity 1—Capability Expansion for CM in APAC (continued)
Growth Opportunity 2—Focus on Process Automation for Enhanced Productivity
Growth Opportunity 2—Focus on Process Automation for Enhanced Productivity (continued)
Growth Opportunity 3—Viral Vector CM for Gene Therapy
Growth Opportunity 3—Viral Vector CM for Gene Therapy (continued)
Next Steps
Your Next Steps
List of Exhibits
Legal Disclaimer